Beta Bionics, Inc. (BBNX)
Company
Beta Bionics, Inc. (BBNX)
Jan 30, 2025
Health
Initial Public Offering / IPOIPO details
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Former names
| Name | Until |
|---|---|
| Beta Bionics, Inc | Jan 6, 2025 |
Chart/Sentiment
Financials
Beta Bionics, Inc. (BBNX)
| Period end | Revenue |
|---|---|
2025-12-3110-K | 100.3 m USD |
2024-12-3110-K | 65.1 m USD |
2023-12-3110-K/A | 12.0 m USD |
Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.







